Pharmacotherapy of obesity: Available medications and drugs under investigation
Eleni Pilitsi(Beth Israel Deaconess Medical Center), Christos S. Mantzoros(Beth Israel Deaconess Medical Center), Aimilia-Eirini Papathanasiou(Brigham and Women's Hospital), Stergios A. Pοlyzos(Aristotle University of Thessaloniki), Olivia M. Farr(Harvard University), Nikolaos Perakakis(Deutsches Diabetes-Zentrum e.V.), Eric Nolen‐Doerr(Boston Medical Center)
Cited by 250
Related Papers
Role of leptin in the neuroendocrine response to fasting
|Nature|1996|3.1k
Adverse metabolic and cardiovascular consequences of circadian misalignment
|Proceedings of the National Academy of Sciences|2009|2.3k
Obesity and cancer risk: Emerging biological mechanisms and perspectives
|Metabolism|2018|1.6k
Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics
|Metabolism|2018|1.2k